Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US

Core Viewpoint - Bristol Myers Squibb plans to launch its schizophrenia treatment Cobenfy in the UK in 2026 at a price equal to its US list price [1] Company Summary - The company is preparing for the introduction of Cobenfy, targeting the UK market for schizophrenia treatment [1] Industry Summary - The launch of Cobenfy in the UK represents a strategic move within the pharmaceutical industry, particularly in the mental health treatment sector [1]